Not All Adverse Events in Clinical Trials Should Be Reported to IRBs

Washington Drug Letter
KEYWORDS Guidances

Individual adverse events in clinical trials are not necessarily the same thing as unanticipated problems and may not have to be reported as such to the institutional review board (IRB), according to new draft guidance from the FDA.

To View This Article:


Buy This Article Now

Add this article to your cart for $10.00